ONCAlert | Upfront Therapy for mRCC

Biosimilars VIEW MORE >>

Bradley J. Monk, MD, noted the FDA’s approval of the biosimilar agent bevacizumab-awwb across multiple indications including metastatic colorectal cancer, non–small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, and cervical cancer, but he wondered aloud why ovarian cancer was not on the list.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.